New research reveals weaknesses in the STOPP/START version 3 criteria, highlighting the need for stronger evidence in geriatric medication management.
Jordyn Belcourt, BSPharm
Advertisement
Articles by Jordyn Belcourt, BSPharm
Polypharmacy poses significant risks for patients, highlighting the need for comprehensive medication reviews and patient involvement.
Advertisement
Latest Updated Articles
Stronger Criteria, Weaker Evidence: Evaluating STOPP/START Version 3 for Geriatric CarePublished: January 21st 2026 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Q&A: How Pharmacists Can Address Structural Barriers in Obesity Care
5